Title: First option drugs in treating heart failure: ACE-inhibitors or B-adrenolytics - new facts
- Łukasz Figiel, Maria Krzemińska-Pakuła
- Review articles
- Polish Journal of Cardiology
- Start page:
- Final page:
- heart failure, p-adrenolytics, ACE-inhibitors, multicenter trials
Heart failure (HF) continues to be one of the most important problem of contemporary cardiology at the be-ginning of XXI century. Development of diagnostic and therapeutic methods based on well understanding of the pathophysiology gives hope for continuous progress in management of heart failure although its pro-per treatment still remains as a common clinical problem and a significant diagnostic and therapeutic chal-lenge. The role of ACE-inhibitors and |3-adrenolytics in the treatment of HF is established and their effecti-veness is well confirmed. According to present standards |3-adrenolitycs are recommended to be initiated after ACE-inhibitors, but such an order is not the result of data collected on base of EBM, but is morę like-ly accidental. The order of initiation of the drugs from both groups is not only an academic discussion but it can be important because many patients cannot tolerate target dose of both. The following article shows pathophysiological causes of HF and summarises contemporary rules for its management basing on results of the latest trials. The Authors of this article present new facts regarding the importance of ACE-inhibitors and |3-adrenolytics in treatment of heart failure and controversions connected with it.